At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 344 enrolled
Drug / intervention
Inhaled loxapine 5 mg +2 moredrug
Likely dose
Inhaled loxapine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation
In Brief
A Phase 3 clinical trial evaluating Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, and 1 other intervention for Patients With Schizophrenia and Acute Agitation. Completed, enrolled 344 participants across 1 site.
Detailed Summary
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedMar 2008
Primary CompletionMay 2008
TodayJul 2026
First PostedMar 5, 2008
Enrollment StartFeb 1, 2008
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.3 years ago
Interventions
Inhaled loxapine 5 mgdrug
Inhaled loxapine 5 mg
Inhaled loxapine 10 mgdrug
Inhaled loxapine 10 mg
Inhaled placebodrug
Inhaled placebo